FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
AI Summary: Corcept Therapeutics has hit a regulatory roadblock as the FDA rejected its cortisol‐targeting relacorilant, intended for hormonal disorders. The decision forces the company to reassess its strategy, highlighting the challenges inherent in advancing novel hormonal therapies amid strict regulatory scrutiny.
Related Stories
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 months
FDA approves Rucaparib for advanced prostate cancer / 6 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 6 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 7 months
FDA Approves Ziftomenib for AML Treatment / 7 months
FDA updates Sarepta gene therapy label with severe warnings / 7 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Diagnostics, Research Funding, Cybersecurity, Government Policy and look for the RSS link.
StackHealth Time Machine